市場調查報告書

連續血糖監測系統的全球市場

Global Continuous Glucose Monitoring Market - 2019 - 2026

出版商 DataM Intelligence 商品編碼 776946
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
連續血糖監測系統的全球市場 Global Continuous Glucose Monitoring Market - 2019 - 2026
出版日期: 2019年12月01日內容資訊: 英文
簡介

本報告提供全球連續血糖監測系統 (CGM) 設備的市場相關分析,提供市場基本結構及最新形勢,整體市場趨勢預測 (今後8年份),各零件及地區別詳細趨勢,主要的推動及阻礙市場要素,市場佔有率結構,主要企業的簡介等相關調查。

第1章 分析範圍·手法

第2章 市場主要趨勢和動靜

第3章 產業分析

  • 推動市場要素
  • 阻礙市場要素
  • 法規方案
  • 波特的五力分析

第4章 全球連續血糖監測系統市場:各市場區隔分析

  • 各零件
    • 發信機 (傳送器)
    • 接收機 (接收器)
    • 感測器
    • 胰島素幫浦
    • 其他

第5章 全球連續血糖監測系統市場:各地區分析

  • 各地區的市場概況
  • 北美 (美國,加拿大,墨西哥)
  • 歐洲 (德國,英國,法國等)
  • 南美 (巴西,阿根廷等)
  • 亞太地區 (中國,印度,日本,澳洲等)
  • 其他的國家 (RoW)

第6章 競爭環境

  • 競爭方案
  • 各製造公司採用的主要策略
  • 產品間的互相比較

第7章 企業簡介

  • Medtronic Plc
  • Dexcom
  • Roche
  • GlySens Incorporated
  • Insulet Corporation
  • Senseonics Incorporated

第8章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Continuous Glucose Monitoring (CGM) Devcies are the advancement in diabetes management, where the blood glucose is under continuous monitor. The conventional glucose monitoring devices require finger pricks to check the glucose level in the blood, however, CGM does not require finger pricks everytime.

The introduction of CGM devices integrated with insulin pumps using transmitters, receivers, and glucose sensors also increased their adoption due to improved convenience. The process of data collection through CGM has helped people keep track of their daily glucose levels. The intake of insulin based on the glucose level data helps the patients to stay healthy and avoid hypoglycemia and hyperglycemia.

The global continuous glucose monitoring market is expected to grow at a CAGR of XX% to reach market value of USD XXXX million by 2026.

Global Continuous Glucose Monitoring Market 2017-2026, in USD Million

2017 14,362

2018 15,242

2019 16,274

2026 27,650

Market Drivers:

Growing prevalence of diabetes in developed and emerging economies play a vital role in market growth over the forecast period.

In 2015, approximately 415 million people in the world had diabetes, which is expected to increase to around 642 million by 2040. As of 2015, it has been estimated that 9.1% adults in the world have diabetes and this is expected to increase to 10% by 2040. In addition, 75%-80% of the individuals with diabetes belonged to low- and middleincome countries. The number of people with diabetes is high in APAC. According to OECD, the prevalent cases are going to reach about 47,973,000 in Europe, 66,812,000 in the Americas, and 18,234,000 in Africa by 2030. The global prevalence of diabetes was estimated to be 9% among adults aged above 18 years.

It has been estimated that most countries spend 5%-20% of their health expenditure on diabetes. The healthcare spending for diabetes is estimated to increase by 19% by 2040.

Market Restraints:

One of the major factors hindering the Continuous glucose monitoring market is undiagnosed population. It has also been estimated that 25%-27% of people with diabetes are unaware of their condition. According to the Centers for Disease Control and Prevention, more than 70% of diabetic patients reside in developing and under-developed countries.

Approximately seven million adults in the US suffering from diabetes or one-fourth of the US diabetic population is unaware of its condition.

Market Segmentation

By Component

On the basis of component, insulin pumps hold the major market share and are expected to grow over the forecast period.

Insulin pumps is expected to dominate the market share contributing more than 50%for of the market in the global CGM market in 2018. Some of the prominent insulin pumps are MiniMed 530G and MiniMed 630G from Medtronic.

Key advantages that surpass the market for insulin pump among other components are:

Accessibility: The ease with which these devices can be used to deliver insulin as when required

Minimum injections: The frequency of changing pump tubing is reduced

Easier insulin dosing: Insulin stacking can be avoided due to the calculation of sugar levels by the device

Flexibility: The basal rates can be adjusted as per the patient requirement

Continuous glucose monitoring: Timely readings can be noted

Complete scenario: Daily glucose levels along with the effect of daily food and exercise can be noted

By geography

North America dominates the global continuous glucose monitoring market in 2018. The prevalence of diabetes and associated disorders, such as obesity, are on the rise.

The US was the largest market for the sales of CGM devices in the Americas. The CGM devices market in the Americas is witnessing significant growth, primarily because of the growing prevalence of obesity as well as diabetes. Also, the country is the base for several reputable companies in the market. Other factors such as the introduction of new technologies that continuously monitor glucose itself, levels and the increasing FDA approvals for new products are driving the market growth in this region.

Followed by, Europe, the next most dominant market for continuous glucose monitoring market with high CAGR over the forecast period. The increased awareness about integrating digital technology and advanced CGM devices to monitor glucose levels and manage insulin delivery has further fuelled the market growth. Improved healthcare infrastructure and the introduction of patient-specific glucose monitoring devices in Western parts of Europe is expected to propel the growth of the market over the forecast period.

Market share of Global Continuous Glucose Monitoring Market by Region, 2018

North America 38.32%

Asia Pacific 27.71%

Europe 23.03%

South America 6.24%

ROW 4.70%

Competitive Landscape

The Dexcom CGM and its mobile apps Follow and Share 2 are the first mobileconnected systems approved by the US FDA. This device allows users to directly view the glucose data on their iPhone. Currently, Dexcom provides its devices G4 platinum CGM with Share that supports the Apple watch. Along with this, the users can invite up to five people to view their glucose information, and an alert message can be sent when the user's glucose levels are above normal range.

A number of local players are expected to enter the market because of the high revenue-generating potential of the market.

Competitive toughness will be highly observed among the major players as the CGM market is on rise with multiple products are under the pipeline with varied factors to sustain themselves in the market. Some of the competitive aspects of Medtronic are ;

  • Its latest CGM sensor, Enlite can be worn for six days continuously. This device is comfortable, accurate, and smaller than previous versions.
  • The company has manufacturing sites, R&D facilities and global supply hubs in Europe and the US.

Strategy: The integration of CONTOUR Next Link and CONTOUR Plus Link meters into its MiniMed insulin pump systems enables the wireless transmission of blood glucose results to the insulin pump.

Medtronic offers country-specific products. For instance, in the US, MiniMed 530G device with SmartGuard technology is offered, whereas, outside the US, MiniMed 640G devices are offered.

Target Audience

  • Raw Material Suppliers/ Buyers
  • Product Suppliers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturer

Table of Contents

1. GLOBAL CONTINUOUS GLUCOSE MONITORING MARKET-SCOPE AND METHODOLOGY

  • 1.1. Research Methodology
  • 1.2. Scope of the market

2. GLOBAL CONTINUOUS GLUCOSE MONITORING MARKET - KEY TRENDS AND DEVELOPMENTS

  • 2.1. Key Trends and Developments

3. INDUSTRY ANALYSIS

  • 3.1. Drivers
  • 3.2. Restraints
  • 3.3. Regulatory Scenario
  • 3.4. Porter's Five Forces Analysis

4. GLOBAL CONTINUOUS GLUCOSE MONITORING MARKET SEGMENTATION

  • 4.1. BY COMPONENT
    • 4.1.1. Transmitter
    • 4.1.2. Receiver
    • 4.1.3. Sensor
    • 4.1.4. Insulin pumps
    • 4.1.5. Others

5. GLOBAL CONTINUOUS GLUCOSE MONITORING MARKET - BY GEOGRAPHY

  • 5.1. Geographic Overview
  • 5.2. North America
    • 5.2.1. U.S.
    • 5.2.2. Canada
    • 5.2.3. Mexico
  • 5.3. Europe
    • 5.3.1. Germany
    • 5.3.2. U.K.
    • 5.3.3. France
    • 5.3.4. Rest of Europe
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
    • 5.4.3. Rest of South America
  • 5.5. Asia Pacific
    • 5.5.1. China
    • 5.5.2. India
    • 5.5.3. Japan
    • 5.5.4. Australia
    • 5.5.5. Rest of Asia Pacific
  • 5.6. Rest of World

6. COMPETITIVE LANDSCAPE

  • 6.1. Competitive Scenario
  • 6.2. Key Strategies adopted by Manufacturers
  • 6.3. Product Benchmarking

7. COMPANY PROFILES

  • 7.1. Medtronic Plc
  • 7.2. Dexcom
  • 7.3. Roche
  • 7.4. GlySens Incorporated
  • 7.5. Insulet Corporation
  • 7.6. Senseonics Incorporated

8. APPENDIX

  • 8.1. Sources
  • 8.2. List of Tables
  • 8.3. Expert Panel Validation
  • 8.4. Disclaimer
  • 8.5. Contact Us